FRANKFORT, Ky. (AP) - Kentucky's Medicaid program will receive
more than $135,000 in a settlement with the manufacturer of a
cystic fibrosis drug.
Attorney General Jack Conway announced Wednesday that Kentucky
was part of a $75.2 million settlement with Novartis
The settlement with the Switzerland-based company resolves
claims that Novartis had knowingly promoted the sale and use of
tobramycin for uses not approved by the U.S. Food & Drug
Kentucky will receive more than $470,000, which is double the
amount the state's Medicaid program spent on prescriptions written
as a result of the company's off-label marketing. After reimbursing
the federal government for its contribution, the Kentucky Medicaid
program will retain $136,199.
(Copyright 2010 by The Associated Press. All Rights Reserved.)